Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS4Dependence: Dextroamphetamine Substitution in Amphetamine- and Opioid-Dependent Adults on OAT
2023-508291-11-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amphetamine dependence and opioid use disorder (OUD) comparing Dexamfetamine substitution with Placebo control (2 arms). Primary endpoints: Illicit amphetamine use (urine tests) and Self-reported amphetamine use (quantity). Planned start Mar 2024; status: authorised.
02
Drugs
adenosine-5′-monophosphate
03
Conditions
amphetamine dependenceopioid use disorder (OUD)
Beyond the preview
Go deeper on 2023-508291-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508291-11-00.